Developing advanced genetic tools to study cancer in personalized tumor models
Official title: Enabling in vivo barcoded single-cell multiomics-compatible genome-wide screens in personalized tumor models using defined-copy somatic transgenesis
Funded at Cedars-Sinai Medical Center · NIH-11031374 · Data updated 2026-11-12
This study is exploring a new way to use CRISPR technology to learn more about how genes affect cancer, which could help create better, personalized treatments for patients like you.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Cedars-Sinai Medical Center NIH-funded |
| Lab location | 1 site (Los Angeles, United States) |
| Project start | February 8, 2024 |
| Project end | January 31, 2027 |
| Funding year | 2025 |
| Award (this year) | $410,332 |
| NIH project number | 5R33CA278564-02 |
| Project ID | NIH-11031374 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include pediatric and adult patients with various types of cancer, particularly those who may benefit from advanced genetic analysis.
✕Less likely to help
Patients with non-cancerous conditions or those who do not have access to the required genetic testing may not receive benefits from this research.
What this research studies
This research focuses on enhancing CRISPR technology to better understand the genetic mechanisms behind cancer. By using a novel method called MADR Perturb-seq, the team aims to conduct large-scale genetic screens in living models, which could lead to more effective cancer treatments. The approach involves non-invasive techniques to introduce genetic changes and analyze their effects on tumor development. Patients may benefit from insights gained through this research that could lead to personalized therapies.
Why it matters
Potential benefit: If successful, this research could lead to breakthroughs in personalized cancer treatments tailored to individual genetic profiles.
How similar studies have gone: Previous research has shown promising results using CRISPR technology for cancer studies, indicating a strong potential for success with this novel approach.
Where this research is happening
-
Cedars-Sinai Medical Center
Los Angeles, United States Active
Researchers
- Principal investigator: Breunig, Joshua John — Cedars-Sinai Medical Center
- Study coordinator: Breunig, Joshua John
Related research
Other NIH-funded projects on the same topics.
-
Lipid signals that control acetyl-CoA and fat metabolism in NAFLD
A study exploring how membrane lipids influence acetyl-CoA metabolism to understand and potentially treat nonalcoholic fatty liver disease (NAFLD).
-
Them1’s role in fat metabolism and MASLD progression
Aims to understand how a fat-regulating protein (Them1) affects energy use in fat and liver, and how this could contribute to MASLD in people who are overweight.
-
Biomarker-guided Immunosuppression in Kidney Transplant Patients
A multicenter study in kidney transplant recipients is testing whether a biomarker score from HLA-DR/DQ can guide changes in immunosuppression to reduce rejection risk and drug toxicity.
-
Alpha5 integrin's role in ALS: how a cell switch worsens disease
Aims to understand how a specific protein called alpha5 integrin in immune cells affects ALS progression and whether blocking it can help extend life.
-
Chlamydia pneumoniae infection and Alzheimer's disease progression
This project looks at whether a common lung infection, Chlamydia pneumoniae, might influence Alzheimer's disease in people and what that could mean for treatment.
-
Them1 Inhibitors to Help Treat Fatty Liver Disease
Aims to develop and test small molecule drugs that block Them1 to help people with non-alcoholic fatty liver disease (NAFLD).
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.